Roche’s Announcement Regarding Enspryng (FDA Accepts Application for Thyroid Eye Disease)

TOKYO, June 30, 2026 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a media release today regarding Enspryng ® (satralizumab), stating that the U.S. Food and Drug Administration (FDA) has accepted its application for the treatment of thyroid eye disease (TED). Please refer to the link below for details of the media release: FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED) https://www.roche.com/media/releases/med-cor-2026-06-30 Trademarks used or mentioned in this release are protected by laws.

The release as fetched from its publisher. chugai-pharm.co.jp ↗